carmustine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 1 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, C | 1 |
| Choi, SH | 1 |
| Kwak, M | 1 |
| Jeong, B | 1 |
| Ko, J | 1 |
| Park, HJ | 1 |
| Choi, S | 1 |
| Jun, JY | 1 |
| So, I | 1 |
1 other study available for carmustine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
TRPC5 channel instability induced by depalmitoylation protects striatal neurons against oxidative stress in Huntington's disease.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Golgi Apparatu | 2020 |